The Clinical Characterization and Biorepository Core (CCBC) provides ORDRCC investigators with access to unique patient collections and new recruitment opportunities to aid their rheumatic disease research programs and to help facilitate their career development. This Core provides a centralized process for patient-oriented research training, patient/control identification and recruitment, and sample processing, as well as access to large collections of patient and control samples with associated clinical, demographic, therapeutic and disease activity measures. Based upon some recent changes in funding, the Clinical Characterization and Biorepository Core will encompass the previous ORDRCC Sample Procurement and Management Core (SPMC), along with samples and data from the historical Lupus Family Registry and Repository, to facilitate the clinical investigation of ORDRCC investigators and junior investigators. The OMRF SPMC was established with the funding of the ORDRCC, and has supported projects from 37 Junior ORDRCC Investigators (both from inside and outside Oklahoma, spanning from South Carolina to Alaska and from Chicago to California) and 19 ORDRCC Center Investigators. The goals of the Clinical Characterization and Biorepository Core are to: 1) Facilitate human subject recruitment, re-contact, consent and compliance. The CCBC ensures that human subject recruitment, clinical assessments and sample donation procedures meet rigorous standards of good clinical practice. By performing services in informed consent, regulatory reporting, oversight of the welfare of clinical study participants, and provision of expert clinical assessments using validated disease activity instruments, the CCBC supports and expands the research opportunities of all ORDRCC investigators. 2) Process and code samples provided to ORDRCC investigators. The CCBC ensures timely, protocol-driven processing, coding, storage and tracking of human biologic samples. 3) Provide samples and associated clinical data to ORDRCC research projects. Extensive clinical, demographic, disease activity and disease damage data exists on patients enrolled with systemic rheumatic diseases. The CCBC will make ORDRCC investigators aware of various patient and control clinical information and associated samples, which will be useful for their various projects. 4) Train ORDRCC junior investigators in human subject research. The ORDRCC helps ensure appropriate HIPAA and human subjects training of all ORDRCC personnel and training of personnel in use of the central OMRF Autoimmune Disease Institute data system.

Public Health Relevance

This CCB Core provides the resources necessary for all ORDRCC Investigators to access human clinical rheumatic disease information and samples to address their scientific needs. This centralized resource provides appropriate training and protection of human subjects, while also facilitating subject participation and provision of samples for a wide variety of rheumatic disease research questions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR053483-08
Application #
8734209
Study Section
Special Emphasis Panel (ZAR1-KM)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
8
Fiscal Year
2014
Total Cost
$202,359
Indirect Cost
$81,907
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Merrill, Joan T; Immermann, Fred; Whitley, Maryann et al. (2017) The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol 69:1257-1266
Young, Kendra A; Munroe, Melissa E; Guthridge, Joel M et al. (2017) Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. Ann Rheum Dis 76:153-158
Zhao, Jian; Ma, Jianyang; Deng, Yun et al. (2017) A missense variant in NCF1 is associated with susceptibility to multiple autoimmune diseases. Nat Genet 49:433-437
Hinks, A; Bowes, J; Cobb, J et al. (2017) Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases. Ann Rheum Dis 76:765-772
Shiboski, Caroline H; Shiboski, Stephen C; Seror, Raphaèle et al. (2017) 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol 69:35-45
Munroe, Melissa E; Pezant, Nathan; Brown, Michael A et al. (2017) Association of IFIH1 and pro-inflammatory mediators: Potential new clues in SLE-associated pathogenesis. PLoS One 12:e0171193
Li, He; Reksten, Tove Ragna; Ice, John A et al. (2017) Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. PLoS Genet 13:e1006820
Aberle, Teresa; Bourn, Rebecka L; Munroe, Melissa E et al. (2017) Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls. Arthritis Care Res (Hoboken) 69:1780-1788
Talsania, Mitali; Scofield, Robert Hal (2017) Menopause and Rheumatic Disease. Rheum Dis Clin North Am 43:287-302
Munroe, Melissa E; Vista, Evan S; Merrill, Joan T et al. (2017) Pathways of impending disease flare in African-American systemic lupus erythematosus patients. J Autoimmun 78:70-78

Showing the most recent 10 out of 265 publications